Researcher reported in Nature in March 2022, that the first two patients who received an infusion of autologous CAR T-cells in 2010 when they were no longer responsive to chemotherapy, remain in remission. Their CAR T-cell population are still proliferating in their blood, remaining functionally active and keeping the cancer at bay. This landmark study offers insight into the long-term effects of CAR T-cell therapy and highlight the potential for this treatment to be used for chemotherapy-resistant blood cancers.

Relevant Information: